We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBenitec Biopharma Inc.

Benitec Biopharma Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
9.17 USD -0.30 ( 3.17%)
Last update at 2026-11-12T15:42:00Z
VOLUME
7374
Market Cap
385.45M

Momentum Score

…

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
8.95
Low
9.39
High
52 Week Price Range
9.85
Low
16.76
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
9.47
Dividend Yield
-
Revenue TTM
0.01M
Revenue Per Share
0.00
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-33.21%
Net Debt
-179.21M
ROCE
-28.88%
Diluted EPS TTM
-0.98

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -45.55M -37.92M -21.75M -19.56M -18.21M
Net income -45.55M -37.92M -21.75M -19.56M -18.56M
Selling general administrative 27.80M 23.43M 6.71M 6.38M 6.65M
Selling and marketing expenses - - 0.28M - -
Gross profit - -0.40M -0.34M 0.07M 0.06M
Reconciled depreciation 0.48M 0.40M 0.34M 0.38M 0.39M
Ebit - -41.77M -21.75M -19.11M -17.85M
Ebitda -51.19M -41.70M -21.41M -18.73M -17.93M
Depreciation and amortization - 0.07M 0.34M 0.38M -0.08M
Operating income -51.19M -41.77M -22.60M -19.08M -17.85M
Other operating expenses - 41.77M 22.60M 19.16M 17.93M
Interest expense - - 0.90M 0.03M 0.03M
Net interest income 5.57M 3.29M 0.90M -0.03M -0.03M
Income tax expense - - -0.62M 0.00M 0.35M
Total revenue 0.00M 0.00M 0.22M 0.07M 0.07M
Total operating expenses 51.19M 41.37M 22.25M 19.16M 17.92M
Cost of revenue - 0.40M 0.34M 0.00M 0.01M
Total other income expense net 5.65M 3.85M 0.85M -0.45M -0.35M
Net income from continuing ops -45.55M -37.92M -21.75M -19.56M -18.21M
Net income applicable to common shares - - - -19.56M -18.21M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 182.62M 99.59M 52.21M 4.46M 5.97M
Other current assets 1.71M 0.74M 0.58M 1.18M 0.76M
Total liab 5.61M 2.30M 4.96M 4.26M 3.09M
Total stockholder equity 177.01M 97.30M 47.25M 0.20M 2.88M
Other current liab 4.85M 1.25M 3.29M 3.70M 0.40M
Common stock 0.00M 0.00M 0.00M - 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -273.72M -228.18M -190.26M -167.89M -148.33M
Other assets - - - 0.12M 0.16M
Cash 179.97M 97.74M 50.87M 2.48M 4.06M
Total current liabilities 5.34M 1.80M 4.92M 3.98M 2.53M
Current deferred revenue - - -1.35M -1.14M -
Net debt -179.21M -96.89M -50.58M -1.92M -3.25M
Short term debt 0.50M 0.35M 0.28M 0.28M 0.25M
Short long term debt total 0.76M 0.85M 0.28M 0.56M 0.81M
Other stockholder equity 451.69M 326.31M 238.40M 168.92M 152.45M
Property plant equipment - - - 0.61M 0.99M
Total current assets 181.69M 98.52M 51.67M 3.73M 4.82M
Net tangible assets - - - 0.20M 2.88M
Net receivables 0.00M 0.03M 0.23M 0.06M 0.00M
Inventory - - 0.06M 0.01M -
Accounts payable 0.91M 0.20M 1.35M 1.14M 1.88M
Accumulated other comprehensive income -0.96M -0.84M -0.89M -0.83M -1.25M
Non currrent assets other 0.07M 0.08M 0.09M 0.12M 0.16M
Non current assets total 0.94M 1.07M 0.54M 0.73M 1.15M
Capital lease obligations 0.76M 0.85M 0.28M 0.56M 0.81M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.02M -0.18M -0.00M -0.01M
Change to liabilities - - - 1.36M 1.09M
Total cashflows from investing activities -0.10M -0.02M -0.18M -0.00M -0.01M
Total cash from financing activities 98.98M 70.48M 68.03M 16.02M 16.02M
Change to operating activities - - - -0.59M -0.05M
Net income -45.55M -37.92M -21.75M -19.56M -18.21M
Change in cash 82.23M 46.93M 48.44M -1.59M -15.71M
Begin period cash flow 97.86M 50.93M 2.49M 4.08M 19.78M
End period cash flow 180.09M 97.86M 50.93M 2.49M 4.08M
Total cash from operating activities -16.52M -23.59M -19.40M -18.01M -15.90M
Issuance of capital stock 104.50M 30.46M 73.92M 17.88M 0.00M
Depreciation 0.48M 0.40M 0.34M 0.38M 0.39M
Dividends paid - - 0.62M - -
Change to account receivables - 0.20M -0.18M -0.05M 0.00M
Other cashflows from financing activities 98.98M - -2.85M -1.87M -0.01M
Change to netincome - - - 0.46M 0.88M
Capital expenditures 0.10M 0.02M 0.18M 0.00M 0.01M
Change in working capital 2.14M -2.73M 1.17M 0.71M 1.04M
Stock based compensation 26.41M 17.43M 0.83M 0.45M 0.87M
Other non cash items 2.14M -0.76M 0.00M 0.72M 0.01M
Free cash flow -16.62M -23.61M -19.58M -18.01M -15.91M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BNTC
Benitec Biopharma Inc.		 -0.30
3.17%		 9.17 - - 2770.13 2.34 10457.68 850.87
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Benitec Biopharma Inc.

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

3940 Trust Way, Hayward, CA, United States, 94545

510 780 0819

https://benitec.com

19

Name Title Year Born
Dr. Jerel A. Banks M.D., Ph.D. Exec. Chairman & CEO 1975
Ms. Megan Joan Boston BComm, CA, Dip., GAICD Exec. Director 1972
Mr. Bryan Dulhunty Chief Financial Officer NA
Dr. Michael Graham Head of Discovery & Founding Scientist NA
Dr. Craig Lewis Chief Medical Adviser NA
Dr. Claudia Kloth Sr. VP of Manufacturing NA
Dr. Jerel A. Banks M.D., Ph.D. Executive Chairman & CEO 1975
Ms. Megan Joan Boston BComm, CA, Dip., GAICD Executive Director 1972
Dr. Claudia Kloth Senior Vice President of Manufacturing NA
Dr. Jerel A. Banks M.D., Ph.D. Executive Chairman & CEO 1976

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…